Myeloma bone disease and proteasome inhibition therapies

Blood

Volumn 110, Issue 4, 2007, Pages 1098-1104

  Terpos, Evangelos ^a,b   Sezer, Orhan ^c   Croucher, Peter ^d   Dimopoulos, Meletios Athanassios ^e  

^a 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; EPOXOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; OSTEOCALCIN; OSTEOPROTEGERIN; PREDNISONE; THALIDOMIDE;

BONE DENSITY; BONE DESTRUCTION; BONE DISEASE; BONE INJURY; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG INHIBITION; ENZYME INHIBITION; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE DIFFERENTIATION;

EID: 34548029349     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-03-067710     Document Type: Review

References (78)

1. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29-40.
2. Epstein J, Walker R. Myeloma and bone disease: "the dangerous tango". Clin Adv Hematol Oncol. 2006;4:300-306.
3. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiologyand management of bone disease in multiple myeloma. Br J Haematol. 2003;123:758-769.
4. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol. 1992;49:192-198.
5. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62-66.
6. Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun. 2005;338:687-693.
7. Heider U, Fleissner C, Zavrski I, et al. Bone markers in multiple myeloma. Eur J Cancer. 2006;42:1544-1553.
8. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005;16:1223-1231.
9. Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood. 2003;101:2094-2098.
10. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98:3527-3533.
11. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98:11581-11586.
12. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002;100:3002-3007.
13. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 2001;98:3534-3540.
14. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res. 2003;9:1436-1440.
15. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor {kappa}B ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102:1064-1069.
16. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002;116:278-290.
17. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96:671-675.
18. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest. 2001;108:1833-1841.
19. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100:2195-2202.
20. Terpos E, Politou M, Szydlo R, et al. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol. 2003;123:106-109.
21. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003;102:311-319.
22. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol. 2005;33:272-278.
23. Masih-Khan E, Trudel S, Heise C, et al. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood. 2006;108:3465-3471.
24. Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005;65:1700-1709.
25. Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 2004;103:2308-2315.
26. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood. 1996;88:3998-4004.
27. Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484-2491.
28. Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol. 2003;122:39-52.
29. Silvestris F, Cafforio P, Calvani N, Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol. 2004;126:475-486.
30. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005;106:2472-2483.
31. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006;108:3992-3996.
32. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8:739-750.
33. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-2494.
34. Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006;119:1728-1731.
35. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005;106:3160-3165.
36. Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005;106:1407-1414.
37. UK myeloma forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol. 2001;115:522-540.
38. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-3736.
39. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047-1053.
40. Terpos E, Rahemtulla A. Bisphosphonate treatment for multiple myeloma. Drugs Today. 2004;40:29-40.
41. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res. 2003;18:482-492.
42. Gordon S, Helfrich MH, Sati HI, et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol. 2002;119:475-483.
43. Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J. Proteasome inhibition in multiple myeloma. Eur J Cancer. 2006;42:1623-1639.
44. Zavrski I, Kleeberg L, Kaiser M, et al. Proteasome as an emerging therapeutic target in cancer. Curr Pharm Design. 2007;13:471-485.
45. Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood. 2007;109:2100-2105.
46. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78:773-785.
47. Zavrski I, Krebbel H, Wildemann B, et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun. 2005;333:200-205.
48. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003;111:1771-1782.
49. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-172.
50. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
51. Terpos E, Rahemtulla A, Dimopoulos MA. Current treatment options for myeloma. Expert Opin Pharmacother. 2005;6:1127-1142.
52. Oyajobi BO, Garrett IR, Gupta A, et al. Role of Dickkopf 1 (DKK) in myeloma bone disease and modulation by the proteasome inhibitor Velcade. J Bone Miner Res. 2004;19:abstract 1011.
53. Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007;110:334-338.
54. Mukherjee S, Raje N, Patel C, et al. Bortezomib induces proliferation of mesenchymal progenitor cells and promotes differentiation towards osteoblastic lineage [abstract]. Blood. 2006;108:30a. Abstract 88.
55. Pennisi A, Ling W, Perkins P, et al. PTH and bortezomib suppress growth of primary human myeloma through increased bone formation in vivo [abstract]. Blood. 2006;108:154a. Abstract 509.
56. Kawanabe N, Anderson K, Lorenzo JA. Bortezomib, a novel proteasome inhibitor, approved for use in multiple myeloma, inhibits osteoclast formation and function. J Bone Miner Res. 2004;19:abstract SU337.
57. Zavrski I, Hecht M, Krebbel H, et al. Bortezomib inhibits human osteoclastogenesis [abstract]. Blood. 2006;108:406a. Abstract 1395.
58. Breitkreutz I, Vallet S, Raab MS, et al. Lenalidomide and bortezomib inhibit osteoclast differentiation and activation in multiple myeloma: clinical implications [abstract]. Blood. 2006;108:993a. Abstract 3485.
59. Feng R, Oton AB, Patrene K, et al. Combination of the proteasome inhibitor bortezomib and a histone deacetylase inhibitor PXD101 results in synergistic inhibition of osteoclastogenesis and significantly stronger inhibition of multiple myeloma growth in vitro and in vivo [abstract]. Blood. 2006; 108:153a. Abstract 507.
60. Nakamura T, Kukita T, Shobuike T, et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol. 2005;175:5809-5816.
61. Boissy P, Lund T, Andersen TL, Plesner T, Delaisse JM. Bortezomib transiently inhibits osteoclast resorptive activity in cell culture conditions mimicking in vivo intermittent treatment [abstract]. Blood. 2006;108:1000a. Abstract 3508.
62. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131:71-73.
63. Shimazaki C, Uchida R, Nakano S, et al. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia. 2005;19:1102-1103.
64. Zangari M, Barlogie B, Lee CK, et al. Increment in bone phophatase (ALP) in myeloma patients during treatment with Velcade, thalidomide and dexamethasome (VTD) is a strong predictor for response [abstract]. Blood. 2003;102:687a. Abstract 2544.
65. Zangari M, Najarian KB, Esseltine DL, et al. The anti-myeloma effect of bortezomib is associated with osteoblastic activity [abstract]. Blood. 2005;106:152a. Abstract 510.
66. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma. 2006;7:109-114.
67. Yaccoby S, Wezeman MJ, Zangari M, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006;91:192-199.
68. Heider U, Kaiser M, Muller C, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol. 2006;77:233-238.
69. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006;135:688-692.
70. Terpos E, Anagnostopoulos A, Heath D, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1α and angiogenic cytokines [abstract]. Blood. 2006;108:1010a. Abstract 3541.
71. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
72. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun. 2005;329:177-181.
73. Peles S, Fisher NM, Gao F, Tomasson MH, Dipersio JF, Vij R. A prospective study of the effects of once weekly bortezomib on markers of bone metabolism in patients with multiple myeloma (MM) [abstract]. J Clin Oncol. 2006;24:433s. Abstract 7548.
74. Terpos E, de la Fuente J, Szydlo R, et al. Tartrateresistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer. 2003;106:455-457.
75. Terpos E, Politou M, Szydlo R, et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia. 2004;18:1420-1426.
76. Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia. 2005;19:1969-1976.
77. Tosi P, Zamagni E, Cellini C, et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol. 2006;76:399-404.
78. von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia. Prepublished on June 21, 2007, as DOI 10.1038/sj.leu.2404806.